Who is sponsoring NCT05185544?

NCT05185544 is sponsored by Shanghai Zhongshan Hospital.

What drugs are being tested in NCT05185544?

Interventions in NCT05185544: Neoadjuvant pemetrexed and cisplatin chemotherapy.

What condition does NCT05185544 study?

NCT05185544 studies Sensitivity.

Is NCT05185544 still recruiting?

NCT05185544 is currently status unknown. Last updated 11 January 2022.

Last reviewed 2022-01-11 · How we verify

NCT05185544

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Combining Genomics and Imageomics to Predict the Sensitivity of Neoadjuvant Pemetrexed and Cisplatin Chemotherapy in Patients With Lung Adenocarcinoma

Status unknown Last updated 11 January 2022

What this trial tests

trial testing Neoadjuvant pemetrexed and cisplatin chemotherapy in Sensitivity in 50 participants. Status unknown.

Timeline

1 January 2022

Primary endpoint
31 December 2024

31 December 2024

Quick facts

Lead sponsor	Shanghai Zhongshan Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	50
Start date	1 January 2022
Primary completion	31 December 2024
Estimated completion	31 December 2024

Drugs / interventions tested

Neoadjuvant pemetrexed and cisplatin chemotherapy

Conditions studied

Sensitivity — all drugs for Sensitivity →

Sponsor

Shanghai Zhongshan Hospital

Who can join

Adults 18 to 75, any sex, with Sensitivity. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Combining genomics and imageomics to predict the sensitivity of neoadjuvant pemetrexed and cisplatin chemotherapy in patients with lung adenocarcinoma

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Zhongshan Hospital trials

Trials by the same sponsor.

NCT07353476 — Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN⁺M0 NSCLC · Phase 2 · not yet recruiting
NCT07508956 — Feasibility of Circulating Tumor DNA Based Minimal Residual Disease-Guided Adjuvant Therapy in Locally Advanced Gastric · Phase 3 · not yet recruiting
NCT07535632 — SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cance · Phase 2 · not yet recruiting
NCT07531368 — BBAP With CS Mapping Guidance · NA · not yet recruiting
NCT07501104 — Neoadjuvant Pucotenlimab Combined With Lenvatinib and Temozolomide in Resectable Stage IIB/III Acral Melanoma · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05185544 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Zhongshan Hospital
Last refreshed: 11 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05185544.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing